Medical Moment One: Novel Pharmacologic Approaches in a Symptomatic, High-risk HFrEF Patient Population

Join Drs. Muthiah Vaduganathan and Javed Butler for this on-demand online activity, as they examine novel methodologies to address the clinical worsening of HFrEF, with a focus on recently-reported results from the VICTORIA trial.


Supported through an independent educational grant from Merck.

Target Audience

Cardiologists and primary care physicians, alongside their interprofessional heart failure care team of nurse practitioners (NPs) and physician assistants (PAs).

Learning Objectives

  • Explore the importance of clinical worsening of heart failure and its subsequent impact on treatment decisions and patient morbidity and mortality.
  • Examine recently-reported results from the VICTORIA trial, with an incisive emphasis on how novel pharmacologic approaches (sGC stimulation) can reduce heart failure hospitalization and readmission rates in patients with evidence of clinical worsening.
  • Evaluate the prospective role of biomarkers in the heart failure management paradigm, focusing on natriuretic peptides (NT-proBNP) and troponin, and explore the resultant implications on heart failure diagnosis, prognostication, and treatment.

Additional Information

AttachmentSize
PDF icon Handout1.99 MB
PDF icon References457.56 KB
PDF icon General Information1.95 MB
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Course opens: 
05/10/2021
Course expires: 
05/10/2022
Rating: 
0
On-Demand Enduring Activity
United States

Muthiah Vaduganathan, MD, MPH (Chair)
Instructor in Medicine
Harvard Medical School
Brigham and Women’s Hospital
Cardiovascular Medicine
Boston, Massachusetts

Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications. 

Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media / CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.

 

Javed Butler, MD, MPH, MBA
Patrick H. Lehan Chair Cardiovascular Research
Professor & Chairman Department of Medicine 
University of Mississippi Medical Center
Jackson, Mississippi

 

Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that. 

He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University. 

Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association. 

Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.

Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa. He also receives grant/research support from Amgen, AstraZeneca, and Boehringer Ingelheim and is on the speakers' bureau for Novartis and Roche Diagnostics.

Speakers:
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa. He also receives grant/research support from Amgen, AstraZeneca, and Boehringer Ingelheim and is on the speakers' bureau for Novartis and Roche Diagnostics.

Javed Butler, MD, MPH, MBA–has disclosed that he is a consultant for Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Sequana Medical, and Vifor. He is on the speakers' bureau for AstraZeneca, BI-Lilly, Janssen, and Novartis.

Peer Reviewers:
Terri Cook, PharmD, BCPC, AACC–has no relevant financial relationships to disclose in relation to the content of this activity.

Ravi B Patel, MD, MSc–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 


Medicine (ACCME)
CEC designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™ per webinar. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Please login or register to take this course.